Invention Grant
- Patent Title: Amino compounds for treatment of complement mediated disorders
-
Application No.: US16246832Application Date: 2019-01-14
-
Publication No.: US10689409B2Publication Date: 2020-06-23
- Inventor: Venkat Rao Gadhachanda , Akihiro Hashimoto , Godwin Pais , Qiuping Wang , Dawei Chen , Xiangzhu Wang , Atul Agarwal , Milind Deshpande , Jason Allan Wiles , Avinash Phadke
- Applicant: Achillion Pharmaceuticals, Inc.
- Applicant Address: US CT New Haven
- Assignee: Achillion Pharmaceuticals, Inc.
- Current Assignee: Achillion Pharmaceuticals, Inc.
- Current Assignee Address: US CT New Haven
- Agency: Knowles Intellectual Property Strategies, LLC
- Main IPC: C07D471/04
- IPC: C07D471/04 ; C07F9/572 ; C07D209/42 ; C07D403/12 ; C07D403/14 ; C07D401/14 ; C07D417/06 ; C07F9/6561 ; C07F5/02 ; C07D403/06 ; C07D417/14 ; C07F7/08 ; C07D413/14 ; C07D487/04 ; C07D405/14 ; C07D403/08 ; C07D413/06 ; C07F9/6558 ; A61K31/404 ; A61K31/407 ; A61K31/4162 ; A61K31/4178 ; A61K31/4184 ; A61K31/4188 ; A61K31/4192 ; A61K31/437 ; A61K31/4439 ; A61K31/4709 ; A61K31/496 ; A61K31/506 ; A61K31/549 ; A61K31/55 ; A61K31/675 ; A61K31/683 ; C07B59/00 ; C07D209/14 ; C07D209/40 ; C07D405/12 ; C07D417/12 ; C07D487/14 ; C07D491/113 ; C07D495/04 ; C07D513/04 ; A61K9/00 ; A61K31/4045 ; A61K31/444 ; A61K31/501 ; A61K31/519 ; C07D209/12 ; C07D209/30 ; C07D209/44 ; C07D209/88 ; C07D471/08

Abstract:
Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R12 or R13 on the A group is an amino substituent (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.
Public/Granted literature
- US20190144473A1 AMINO COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS Public/Granted day:2019-05-16
Information query